Luca Giovanni Campana

Dr. Luca Giovanni Campana

Manchester University NHS Foundation Trust, Manchester, UK
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2009 in Annals of Surgical Oncology
Verified
Journal Article
Closed access
PDF file
Luca Giovanni CampanaLuca Giovanni Campana
Luca Giovanni Campana
SMSimone Mocellin
Simone Mocellin
MBMichela Basso
Michela Basso
OPOliviero Puccetti
Oliviero Puccetti
GSGian Luca De Salvo
Gian Luca De Salvo
DNDonato Nitti
Donato Nitti

2 July 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
SVSara Valpione
Sara Valpione
PMPiyushkumar A. Mundra
Piyushkumar A. Mundra
EGElena Galvani
Elena Galvani
Luca Giovanni CampanaLuca Giovanni Campana
Luca Giovanni Campana
PLPaul Lorigan
Paul Lorigan
RMRichard Marais
Richard Marais
Tumor infiltration by T cells is paramount for effective anti-cancer immune responses. We hypothesized that the T cell receptor (TCR) repertoire of tumor infiltrating T lymphocytes could therefore be indicative of the functional state of these cells and determine disease course at different stages in cancer progression. Here we show that the diversity of the TCR of tumor infiltrating T cell at baseline is prognostic in various cancers, whereas the TCR clonality of T cell infiltrating metastatic melanoma pre-treatment is predictive for activity and efficacy of PD1 blockade immunotherapy.

21 November 2012 in Medical & Biological Engineering & Computing
Verified
Journal Article
Open access
PDF file
DMDamijan Miklavčič
Damijan Miklavčič
GSG. Serša
G. Serša
EBE. Brecelj
E. Brecelj
Karen Julie GehlKaren Julie Gehl
Karen Julie Gehl
DSD. Soden
D. Soden
TJT. Jarm
T. Jarm
Electrochemotherapy, a combination of high voltage electric pulses and of an anticancer drug, has been demonstrated to be highly effective in treatment of cutaneous and subcutaneous tumors. Unique properties of electrochemotherapy (e.g., high specificity for targeting cancer cells, high degree of localization of treatment effect, capacity for preserving the innate immune response and the structure of the extracellular matrix) are facilitating its wide spread in the clinics. Due to high effectiveness of electrochemotherapy in treatment of cutaneous and subcutaneous tumors regardless of histological origin, there are now attempts to extend its use to treatment of internal tumors. To advance the applicability of electrochemotherapy to treatment of internal solid tumors, new technological developments are needed that will enable treatment of these tumors in daily clinical practice. New electrodes through which electric pulses are delivered to target tissue need to be designed with the aim to access target tissue anywhere in the body. To increase the probability of complete tumor eradication, the electrodes have to be accurately positioned, first to provide an adequate extent of electroporation of all tumor cells and second not to damage critical healthy tissue or organs in its vicinity. This can be achieved by image guided insertion of electrodes that will enable accurate positioning of the electrodes in combination with patient-specific numerical treatment planning or using a predefined geometry of electrodes. In order to be able to use electrochemotherapy safely for treatment of internal tumors located in relative proximity of the heart (e.g., in case of liver metastases), the treatment must be performed without interfering with the heart’s electrical activity. We describe recent technological advances, which allow treatment of liver and bone metastases, soft tissue sarcomas, brain tumors, and colorectal and esophageal tumors. The first clinical experiences in these novel application areas of electrochemotherapy are also described.

11 April 2018 in Journal of Translational Medicine
Verified
Journal Article
Open access
PDF file
SVSara Valpione
Sara Valpione
SPSandro Pasquali
Sandro Pasquali
Luca Giovanni CampanaLuca Giovanni Campana
Luca Giovanni Campana
LPLuisa Piccin
Luisa Piccin
Simone MocellinSimone Mocellin
Simone Mocellin
VCVanna na Chiarion-Sileni
Vanna na Chiarion-Sileni
Ipilimumab is a licensed immunotherapy for metastatic melanoma patients and, in the US, as adjuvant treatment for high risk melanoma radically resected. The use of ipilimumab is associated with a typical but unpredictable pattern of side effects. The purpose of this study was to identify clinical features and blood biomarkers capable of predicting ipilimumab related toxicity. We performed a prospective study aimed at analyzing potential clinical and biological markers associated with immune-related toxicity in patients treated with ipilimumab (3 mg/kg, q3w). We enrolled 140 consecutive melanoma patients treated with ipilimumab for metastatic disease. The following prospectively collected data were utilized: patient characteristics, previous therapies, level of circulating biomarkers associated with tumour burden or immune-inflammation status (lactic dehydrogenase, C-reactive protein, β2-microglobulin, vascular endothelial growth factor, interleukin-2, interleukin-6, S-100, alkaline phosphatase, transaminases) and blood cells subsets (leukocyte and lymphocyte subpopulations). Logistic regression was used for multivariate analysis of data. Out of 140 patients, 36 (26%) experienced a severe adverse event, 33 (24%) discontinued treatment for severe toxicity. Among the immune-profile biomarkers analyzed, only interleukin-6 was associated with the risk of toxicity. Female patients had a further increase of immune-related adverse events. Low baseline interleukin-6 serum levels (OR = 2.84, 95% CI 1.34–6.03, P = 0.007) and sex female (OR = 1.5, 95% CI 1.06–2.16 P = 0.022) and were significant and independent risk factors for immune related adverse events. Baseline IL6 serum levels and female sex were significantly and independently associated with higher risk of severe toxicity and could be exploited in clinical practice to personalize toxicity surveillance in patients treated with ipilimumab.

1 February 2019 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
Luca Giovanni CampanaLuca Giovanni Campana
Luca Giovanni Campana
IEIbrahim Edhemovic
Ibrahim Edhemovic
DSDeclan Soden
Declan Soden
Anna PerroneAnna Perrone
Anna Perrone
MSMarco Scarpa
Marco Scarpa
GSGregor Sersa
Gregor Sersa

16 February 2016 in Radiology and Oncology
Verified
Journal Article
Open access
PDF file
Luca Giovanni CampanaLuca Giovanni Campana
Luca Giovanni Campana
ACA. James P. Clover
A. James P. Clover
SVSara Valpione
Sara Valpione
PQPietro Quaglino
Pietro Quaglino
Karen Julie GehlKaren Julie Gehl
Karen Julie Gehl
Gregor SersaGregor Sersa
Gregor Sersa
Background: Electrochemotherapy is becoming a well-established treatment for malignancies of skin and non-skin origin and its use is widening across Europe. The technique was developed and optimized from solid experimental and clinical evidence. A consensus document is now warranted to formalize reporting results, which should strengthen evidence-based practice recommendations. This consensus should be derived from high quality clinical data collection, clinical expertise and summarizing patient feedback. The first step, which is addressed in this paper, aims to critically analyze the quality of published studies and to provide the recommendations for reporting clinical trials on electrochemotherapy.Methods: The quality of reporting in published studies on electrochemotherapy was analyzed in order to produce procedure specific reporting recommendations. A comprehensive literature search of studies published from 2006 to 2015 was performed followed by qualitative analysis of manuscripts assessing for 47 quality criteria grouped into four major clusters: (1) trial design, (2) description of patient population, (3) description of treatment delivery and patient outcome, (4) analysis of results and their interpretation. The summary measure during literature assessment was the proportion of studies fulfilling each manuscript quality criteria.Results: A total of 56 studies were screened, from the period 2006 to 2015, of which 33 were included in the qualitative analysis, with a total of 1215 patients. Overall, the quality of reporting was highly variable. Twenty-four reports (73%) were single-center, non-comparative studies, and only 15 (45%) were prospective in nature (only 2 of them were entered into a clinical trials registry). Electrochemotherapy technique was consistently reported, with most studies (31/33) adhering closely to published standard operating procedures. The quality of reporting the patient population was variable among the analyzed studies, with only between 45% and 100% achieving dedicated quality criteria. Reporting of treatment delivery and patient outcome was also highly variable with studies only fulfilling between 3% and 100%. Finally, reporting study results critically varied, fulfilling from 27% to 100% of the quality criteria. Based on the critical issues emerging from this analysis, recommendations and minimal requirements for reporting clinical data on electrochemotherapy were prepared and summarized into a checklist.Conclusions: There is an increasing body of published clinical data on electrochemotherapy, but more high quality clinical data are needed. Published papers often lack accurate description of study population, treatment delivery as well as patient outcome. Our recommendations, provided in the form of a summary checklist, are intended to ameliorate data reporting in future studies on electrochemotherapy and help researchers to provide a solid evidence basis for clinical practice.